Dominik Witzigmann
Overview
Explore the profile of Dominik Witzigmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
3339
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Francia V, Zhang Y, Cheng M, Schiffelers R, Witzigmann D, Cullis P
Proc Natl Acad Sci U S A
. 2024 Mar;
121(11):e2307803120.
PMID: 38437542
Lipid nanoparticle (LNP) formulations are a proven method for the delivery of nucleic acids for gene therapy as exemplified by the worldwide rollout of LNP-based RNAi therapeutics and mRNA vaccines....
2.
Bolsoni J, Liu D, Mohabatpour F, Ebner R, Sadhnani G, Tafech B, et al.
ACS Nano
. 2023 Nov;
17(21):22046-22059.
PMID: 37918441
Despite exciting advances in gene editing, the efficient delivery of genetic tools to extrahepatic tissues remains challenging. This holds particularly true for the skin, which poses a highly restrictive delivery...
3.
Chander N, Basha G, Cheng M, Witzigmann D, Cullis P
Mol Ther Methods Clin Dev
. 2023 Aug;
30:235-245.
PMID: 37564393
Lipid nanoparticles (LNPs) for delivery of mRNA usually contain ionizable lipid/helper lipid/cholesterol/PEG-lipid in molar ratios of 50:10:38.5:1.5, respectively. These LNPs are rapidly cleared from the circulation following intravenous (i.v.) administration,...
4.
Cheng M, Leung J, Zhang Y, Strong C, Basha G, Momeni A, et al.
Adv Mater
. 2023 May;
35(31):e2303370.
PMID: 37172950
The transfection potency of lipid nanoparticle (LNP) mRNA systems is critically dependent on the ionizable cationic lipid component. LNP mRNA systems composed of optimized ionizable lipids often display distinctive mRNA-rich...
5.
Zimmermann C, Baldassi D, Chan K, Adams N, Neumann A, Porras-Gonzalez D, et al.
J Control Release
. 2022 Sep;
351:137-150.
PMID: 36126785
While all the siRNA drugs on the market target the liver, the lungs offer a variety of currently undruggable targets which could potentially be treated with RNA therapeutics. Hence, local,...
6.
Al Fayez N, Rouhollahi E, Ong C, Wu J, Nguyen A, Bottger R, et al.
J Control Release
. 2022 Sep;
350:630-641.
PMID: 36058352
Hepatitis B virus (HBV) can rapidly replicate in the hepatocytes after transmission, leading to chronic hepatitis, liver cirrhosis and eventually hepatocellular carcinoma. Interferon-α (IFN-α) is included in the standard treatment...
7.
Al Fayez N, Bottger R, Ghosh S, Nakajima Y, Chao P, Rouhollahi E, et al.
Int J Pharm
. 2022 Aug;
625:122107.
PMID: 35964828
Many medicines are only available in solid dosage forms suitable for adults, and extemporaneous compounding is required to prepare formulations for children. However, this common practice often results in inaccurate...
8.
Hald Albertsen C, Kulkarni J, Witzigmann D, Lind M, Petersson K, Simonsen J
Adv Drug Deliv Rev
. 2022 Jul;
188:114416.
PMID: 35787388
Lipid nanoparticles (LNPs) play an important role in mRNA vaccines against COVID-19. In addition, many preclinical and clinical studies, including the siRNA-LNP product, Onpattro®, highlight that LNPs unlock the potential...
9.
Quick J, Dos Santos N, Cheng M, Chander N, Brimacombe C, Kulkarni J, et al.
J Control Release
. 2022 Jul;
349:174-183.
PMID: 35780952
Advanced-stage prostate cancer remains an incurable disease with poor patient prognosis. There is an unmet clinical need to target androgen receptor (AR) splice variants, which are key drivers of the...
10.
Basha G, Cottle A, Pretheeban T, Chan K, Witzigmann D, Young R, et al.
Mol Ther
. 2022 Jun;
30(9):3034-3051.
PMID: 35733339
Approved drugs for the treatment of osteoporosis can prevent further bone loss but do not stimulate bone formation. Approaches that improve bone density in metabolic diseases are needed. Therapies that...